Accordingly, rats injected with NO-donors recovered from induced allodynia after either BIBN4096 or ML67-33 treatment in a similar manner, suggesting that TREK activation may prevent CGRP release to suppress migraine phenotype. Here, KCNK2 is linked to migraine disorder.